uniQure NV (LTS:0EE0)
$ 6.32 -0.73 (-10.35%) Market Cap: 312.44 Mil Enterprise Value: -55.20 Mil PE Ratio: 0 PB Ratio: 5.60 GF Score: 73/100

Uniqure NV at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 09, 2020 / 09:15PM GMT
Release Date Price: $41.79 (-0.33%)
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

(technical difficulty)

And maybe share with us kind of the strategic vision. The company has kind of, I think, really starting to define itself in this past couple of years here and going forward. Maybe speak from that perspective. And We'll jump into the programs from there?

Questions & Answers

Matthew Craig Kapusta
uniQure N.V. - CEO, CFO & Executive Director

Yes. Yes, I appreciate that. First, let me just thank you, Marty, and Credit Suisse for having us here at the conference. We're delighted to attend. And I'm also here with Dr. Ricardo Dolmetsch who's our President of R&D as well, who will be helping me answer some of the questions that you might have. Just in terms of a brief introduction, so uniQure which was founded in 1998, in our view, is 1 of the pioneers within what has been a fast emerging space of gene therapy. Back in 2012, uniQure was able to get the first approved gene therapy in the Western world, a product

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot